首页> 美国卫生研究院文献>Marine Drugs >Actinomycetes for Marine Drug Discovery Isolated from Mangrove Soils and Plants in China
【2h】

Actinomycetes for Marine Drug Discovery Isolated from Mangrove Soils and Plants in China

机译:从中国红树林土壤和植物中分离出的用于海洋药物发现的放线菌

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

The mangrove ecosystem is a largely unexplored source for actinomycetes with the potential to produce biologically active secondary metabolites. Consequently, we set out to isolate, characterize and screen actinomycetes from soil and plant material collected from eight mangrove sites in China. Over 2,000 actinomycetes were isolated and of these approximately 20%, 5%, and 10% inhibited the growth of Human Colon Tumor 116 cells, Candida albicans and Staphylococcus aureus, respectively, while 3% inhibited protein tyrosine phosphatase 1B (PTP1B), a protein related to diabetes. In addition, nine isolates inhibited aurora kinase A, an anti-cancer related protein, and three inhibited caspase 3, a protein related to neurodegenerative diseases. Representative bioactive isolates were characterized using genotypic and phenotypic procedures and classified to thirteen genera, notably to the genera Micromonospora and Streptomyces. Actinomycetes showing cytotoxic activity were assigned to seven genera whereas only Micromonospora and Streptomyces strains showed anti-PTP1B activity. We conclude that actinomycetes isolated from mangrove habitats are a potentially rich source for the discovery of anti-infection and anti-tumor compounds, and of agents for treating neurodegenerative diseases and diabetes.
机译:红树林生态系统是放线菌的主要未开发来源,具有产生生物活性次生代谢物的潜力。因此,我们着手从从中国八个红树林地点收集的土壤和植物材料中分离,表征和筛选放线菌。分离出2000多种放线菌,其中约20%,5%和10%分别抑制人结肠肿瘤116细胞,白色念珠菌和金黄色葡萄球菌的生长,而3%抑制蛋白质酪氨酸磷酸酶1B(PTP1B)。与糖尿病有关。此外,有九种分离物抑制了抗癌相关蛋白极光激酶A,还有三种抑制了与神经退行性疾病有关的蛋白caspase 3。使用基因型和表型程序表征代表性的生物活性分离株,并将其分类为十三属,特别是微单孢菌属和链霉菌属。表现出细胞毒活性的放线菌被分配到七个属,而只有微单孢菌和链霉菌菌株显示出抗PTP1B活性。我们得出的结论是,从红树林生境中分离的放线菌是发现抗感染和抗肿瘤化合物以及治疗神经退行性疾病和糖尿病的药物的潜在丰富来源。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号